No Data
Duory Pharmaceutical (301075.SZ): Expected loss of 53 million to -69 million yuan in 2024.
On January 23, Ge Long Hui reported that Duo Rui Pharmaceutical (301075.SZ) expects a loss of 53 million yuan to -69 million yuan in 2024, with a non-recurring loss of 56 million yuan to -73 million yuan. (1) Due to the impact of policies such as pharmaceutical price linkage, the price of the company’s core product, sodium acetate Ringer's injection, has significantly declined. (2) The Phase II clinical trial of the Traditional Chinese Medicine class 1 new drug Yi Fei Ji Sheng granules has been completed with patient enrollment, leading to increased related costs. (3) The initial production costs of some intermediate products are relatively high, resulting in a negative gross margin and the provision for inventory impairment. (4) SiChuan Duo Rui Pharmaceutical Co., Ltd.
Dorui Pharmaceuticals: 2024 Annual Results Forecast
Duorui Medicine (301075.SZ): Currently, all workshops built by Xinchengda have been put into production, and the production operation situation is normal.
On January 10, Gelonghui reported that Duori Pharmaceutical (301075.SZ) stated on the investor interaction platform that all the workshops of Xinchengda have been put into production, and the production and Operation situation is normal. For specific details, please pay attention to the company's announcements and regular reports.
Duori Pharmaceutical (301075.SZ): Own products have not yet been developed for influenza or antiviral treatment.
Gelonghui, January 10 - Duory Pharmaceutical (301075.SZ) stated on the investor interaction platform that the company's ibuprofen suspension is produced based on a sales-driven production model, and the company's own products have not yet been developed for the treatment of influenza or viral infections.
Duori Pharmaceutical (301075.SZ): Sodium Acetate Ringer's Injection (specification packaging 500ml/bag) is expected to be selected for centralized procurement.
On December 16, Gelonghui reported that Duroy Pharmaceutical (301075.SZ) announced that its wholly-owned subsidiary Hubei Duroy Pharmaceutical Co., Ltd. recently participated in the bidding of the tenth batch of national organized centralized procurement of pharmaceuticals organized by the National Organization of Pharmaceutical Joint Procurement Office. According to the public notice of the proposed selected results, the company’s product sodium acetate Ringer's injection (package specification 500ml/bag) is proposed to be selected for this centralized procurement, while sodium bicarbonate Ringer's injection was not selected for this centralized procurement.
Doray Pharmaceuticals (301075.SZ): The target of the acquisition has passed the pharmaceutical GMP compliance inspection and the active pharmaceutical ingredient has been approved for listing.
Gelonghui Nov 6th │ Duorui Pharmaceuticals (301075.SZ) announced that recently, the company's controlling subsidiary, Changdu Rui Le Kang Enterprise Management Co., Ltd., intends to acquire the subject Sichuan FrontBio Pharmaceutical Co., Ltd., approved by the National Medical Products Administration to issue the "Chemical Raw Materials Pharmaceuticals Market Application Approval Notice" (No.: 2024YS01126), approved for domestic production of Ecokin chemical raw materials pharmaceuticals; at the same time, Sichuan FrontBio recently received the "Pharmaceutical GMP Compliance Inspection Notice" (Chuanxu 2024179) issued by the Sichuan Provincial Medical Products Administration, Ecokin active pharmaceutical ingredient production line has passed.
